Get the Stockscreener App
20.12
0.60%
0.09
Innoviva Inc stock is traded at $20.12, with a volume of 11,856.
It is up +0.60% in the last 24 hours and down -2.84% over the past month.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
See More
Previous Close:
$20.03
Open:
$20.01
24h Volume:
11,856
Relative Volume:
0.01
Market Cap:
$1.51B
Revenue:
$384.03M
Net Income/Loss:
$38.65M
P/E Ratio:
64.90
EPS:
0.31
Net Cash Flow:
$196.35M
1W Performance:
+1.31%
1M Performance:
-2.84%
6M Performance:
+4.89%
1Y Performance:
+15.94%
1-Day Range:
$19.88
$20.20
1-Week Range:
$19.43
$20.23
52-Week Range:
$16.52
$22.76
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
20.14 | 1.50B | 384.03M | 38.65M | 196.35M | 0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Sell |
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA - MarketBeat
Avoiding Lag: Real-Time Signals in (INVA) Movement - Stock Traders Daily
Innoviva’s Stock Under the Microscope: Is INVA Quietly Setting Up Its Next Move? - AD HOC NEWS
Innoviva joins elite list of stocks with 95-plus composite rating - MSN
Pacer Advisors Inc. Sells 48,889 Shares of Innoviva, Inc. $INVA - Defense World
Scotiabank Initiates Coverage of Innoviva (INVA) with Sector Outperform Recommendation - MSN
Is Innoviva Inc stock in correction or buying zoneJuly 2025 Reactions & Community Trade Idea Sharing Platform - moha.gov.vn
Despite Lower Earnings Than Five Years Ago, Innoviva (NASDAQ:INVA) Investors Are up 65% Since Then - 富途牛牛
Innoviva (INVA): Valuation Check After FDA Approval of First-in-Class NUZOLVENCE Antibiotic - Sahm
Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Is Innoviva Inc a good long term investmentMarket Sentiment Report & Small Investment Portfolio - earlytimes.in
December 2026 Options Now Available For Innoviva (INVA) - Nasdaq
How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug - Sahm
H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating - Finviz
Technical Reactions to INVA Trends in Macro Strategies - Stock Traders Daily
Will Innoviva Inc. stock attract ESG investorsTrade Exit Report & Daily Profit Maximizing Trade Tips - Улправда
Will Innoviva Inc. (HVE) stock justify high valuation2025 Volatility Report & Weekly Watchlist for Consistent Profits - Улправда
Will Innoviva Inc. (HVE) stock recover faster than industryJuly 2025 Short Interest & High Return Trade Guides - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Can Innoviva Inc. stock deliver surprise earnings beatMarket Growth Summary & Low Drawdown Momentum Ideas - Улправда
Aug Fed Impact: How Innoviva Inc. (HVE) stock compares with tech leadersInsider Selling & Short-Term High Return Ideas - Улправда
Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Weekly Recap & Daily Stock Trend Reports - Улправда
Is Innoviva Still Attractive Around $20 After Strong Multi Year Share Price Gains? - Yahoo Finance
How Innoviva Inc. stock responds to policy changesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - DonanımHaber
Why Innoviva Inc. stock is in analyst buy zoneWeekly Risk Summary & Stock Portfolio Risk Control - DonanımHaber
Is Innoviva Inc. stock positioned for digital transformationJuly 2025 Patterns & Long-Term Capital Growth Strategies - DonanımHaber
Can Innoviva Inc. stock deliver sustainable ROENew Guidance & Low Risk Entry Point Guides - DonanımHaber
Profit Recap: Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Catalysts & Weekly Stock Performance Updates - Улправда
Will Innoviva Inc. stock see PE expansion2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда
Innoviva, Inc. (NASDAQ:INVA) Receives $38.60 Average Target Price from Analysts - Defense World
HC Wainwright & Co. Maintains Innoviva (INVA) Buy Recommendation - Nasdaq
INVA: HC Wainwright & Co. Maintains Buy Rating and Raises Price Target | INVA Stock News - GuruFocus
Innoviva announces Lancet publication of 'positive' Zoliflodacin Phase 3 data - MSN
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - BioSpace
Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence - MSN
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Innoviva (INVA): Revisiting Valuation After a Strong Multi‑Year Share Price Run - Sahm
US FDA approves Innoviva’s oral antibiotic for gonorrhea - WTAQ
US FDA approves Innoviva's oral antibiotic for gonorrhea - Reuters
Innoviva (NASDAQ: INVA) gets FDA approval for single-dose oral antibiotic NUZOLVENCE for gonorrhea - Stock Titan
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - BioSpace
Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 - PharmiWeb.com
Trading the Move, Not the Narrative: (INVA) Edition - Stock Traders Daily
Innoviva, Inc. $INVA Shares Bought by Marshall Wace LLP - MarketBeat
State Board of Administration of Florida Retirement System Cuts Stake in Innoviva, Inc. $INVA - MarketBeat
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Innoviva Inc Stock (INVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | 10% Owner |
Mar 05 '25 |
Sale |
17.63 |
270,374 |
4,766,126 |
6,855,451 |
| DENNER ALEXANDER J | 10% Owner |
Mar 04 '25 |
Sale |
17.63 |
151,175 |
2,665,079 |
7,125,825 |
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):